Faeth Therapeutics will present preclinical PIKTOR findings at ESMO 2026, including combinations with endocrine therapies and direct comparisons with gedatolisib in breast cancer models. The research supports an ongoing Phase 1b/2 trial, but human efficacy results in breast cancer are not yet available.
Find out how Avenzo Therapeutics’ AVZO-023 and AVZO-021 combination study could influence HR+/HER2- breast cancer treatment.
FDA grants breakthrough therapy designation to Relay Therapeutics’ zovegalisib. Find out what this changes for PI3K-mutant breast cancer treatment.
Avenzo shares Phase 1 data on CDK2 inhibitor AVZO-021 in HR+/HER2- breast cancer. Find out what it means for post-CDK4/6 resistance strategies in 2025.